{"name":"AlgoRx Pharmaceuticals","slug":"algorx-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"AlgoRx Pharmaceuticals is a biopharmaceutical company focused on developing innovative treatments for various diseases. The company has two drugs in its pipeline, ALGRX 3268 in Phase 3 and ALGRX 4975 in Phase 2, demonstrating its commitment to advancing medical solutions.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ALGRX 3268","genericName":"ALGRX 3268","slug":"algrx-3268","indication":"Inflammatory bowel disease (IBD)","status":"phase_3"},{"name":"ALGRX 4975","genericName":"ALGRX 4975","slug":"algrx-4975","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ALGRX 3268","genericName":"ALGRX 3268","slug":"algrx-3268","phase":"phase_3","mechanism":"ALGRX 3268 is a selective inhibitor of alginate lyase that modulates the gut microbiome by targeting bacterial polysaccharide degradation.","indications":["Inflammatory bowel disease (IBD)"],"catalyst":""},{"name":"ALGRX 4975","genericName":"ALGRX 4975","slug":"algrx-4975","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQejU1Y1VrOGhXcXQ4WUtER3lIZmxMTkFoSEpoclZfOEpDMHBCSGtTZ24wUHlmbG1ZeGFqS3Mxa1FEWmczc25xVXZtZWlzTThMbEZnNHhNVUZGd2dXSkdJQ1lER1ByNFRFVFpaRW9GaHd6TDNsOGdMaEVIcGEzajZzVWpjdG13Vm96T0ZQRkdMcVE2amxVV3BjS1ZHWGZxSHNTZDJSRldVSThac2VvZ3JaeFdJaDY?oc=5","date":"2021-06-11","type":"regulatory","source":"Fierce Biotech","summary":"Chutes & Ladders—FDA nod for Biogen's Aduhelm sees trio of AdComm members hit the exit - Fierce Biotech","headline":"Chutes & Ladders—FDA nod for Biogen's Aduhelm sees trio of AdComm members hit the exit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE1iNy1JZnltTWN2OWF4WUZpTUEwenI0aU1pS3NTQnBEbDV3SkZmM3d6UzM2LS1jNmJacGV2aTFlRGdpeTlmeVd4MGQtQkRyUTNlOEtpSXZlaVI?oc=5","date":"2020-07-31","type":"pipeline","source":"Pharmaceutical Executive","summary":"New Gains for Pain - Pharmaceutical Executive","headline":"New Gains for Pain","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}